Pentixapharm Holding AG (FRA:PTP) Moat Score: 0/10 (As of Jun. 29, 2026)


FRA:PTP Pentixapharm Holding AG FRA:PTP
20 GF Score
Price €2.20
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Moat Score?

Pentixapharm Holding AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Pentixapharm Holding AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pentixapharm Holding AG might have No Moat - No discernible moat.

Pentixapharm Holding AG  (FRA:PTP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pentixapharm Holding AG Moat Score Related Terms

FRA:PTP
20GF Score
Pentixapharm Holding AG FRA:PTP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Business Description

Other Exchanges PTP:GermanyPTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for FRA:PTP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.20
Price